T-helper 1 immune response (Th1) (Th1)

The T-helper 1 (Th1) immune response is a critical arm of the adaptive immune system primarily responsible for cell-mediated immunity against intracellular pathogens, such as viruses and certain bacteria (StatPearls, NBK538283). It is characterized by the differentiation of CD4+ T cells into Th1 effectors under the influence of interleukin-12 (IL-12) and the master transcription factor T-bet, leading to the secretion of pro-inflammatory cytokines including interferon-gamma (IFN-γ), interleukin-2 (IL-2), and tumor necrosis factor-beta (TNF-β) (Nature Reviews Immunology, 2010). While essential for host defense and anti-tumor surveillance, an exaggerated or persistent Th1 response is a hallmark of various organ-specific autoimmune and chronic inflammatory diseases, such as Crohn's disease, rheumatoid arthritis, and multiple sclerosis (NIH, AI068115). Therapeutic strategies often target this pathway by utilizing monoclonal antibodies to neutralize Th1-driving cytokines or small molecules to inhibit intracellular signaling mediators like JAK1 and STAT4 (PubChem, CID 115998). Because Th1 cells are vital for controlling intracellular infections, clinical inhibition of this response carries a significant risk of reactivating latent infections such as tuberculosis.

Other names

Th1 responseType 1 immunityCell-mediated immunityT-helper type 1 responseTh1-mediated response

Drugs modulate the Th1 response by neutralizing polarizing cytokines like IL-12, inhibiting effector cytokines such as IFN-gamma and TNF-alpha, or blocking downstream JAK/STAT signaling pathways to reduce Th1-mediated inflammation; conversely, adjuvants and immunotherapies may stimulate Th1 activity to enhance cellular defense against pathogens or tumors.